About SPR


SPRINT Addresses Unmet Needs

The Sprint PNS System spans the LARGE TREATMENT GAP that exists between pharmaceuticals and surgery.

Large Underserved Markets

We are actively developing and commercializing therapies aimed at the following large market indications:

Post-surgical pain:
pain following surgery such
as knee replacement,
and rotator cuff repair
Neuropathic pain:
pain following nerve injury
or nerve surgery such as
phantom limb pain
Back Pain
Musculoskeletal pain:
pain in the joints and muscles
such as shoulder pain and
knee pain

Founding & Funding

ndi-logoIntending to build on NDI’s track record of success, SPR Therapeutics was founded in January, 2010 as a portfolio company of NDI Medical, LLC, a hybrid venture capital and commercialization firm focusing exclusively on innovative neurodevice technologies.

NDI sold its first portfolio company, MEDSTIM®, to Medtronic for $42 million in April 2008 returning the original investment back to investors OVER 150 times.

SPR Therapeutics is the recipient of significant non-dilutive funding from multiple grants and loans from the National Institutes of Health, The United States Department of Defense, and the State of Ohio. To learn more, click here to see our press coverage.


SPR Therapeutics is led by an experienced management team with a long history of success in researching, developing and commercializing neurostimulation products. Our clinical and scientific advisors are also renowned worldwide as leaders in interventional pain management, rehabilitation medicine, orthopedics and biomedical engineering.

Executive Management
Maria E. Bennett, President, CEO and FounderSPR-AboutPg-PullQuote
Joseph Boggs, PhD, Vice President of Research and Development
Mark Stultz, Senior Vice President, Market Development

Scientific and Clinical Advisors
John Chae, MD, Chief Medical Advisor
Warren Grill, PhD, Chief Scientific Advisor

Board of Directors
Geoffrey B. Thrope, Chairman
Maria E. Bennett, President, CEO and Founder
Les C. Vinney